NL7900871A - Werkwijze voor de therapeutische behandeling van hyperlipidemie en hyperlipiproteinemie. - Google Patents

Werkwijze voor de therapeutische behandeling van hyperlipidemie en hyperlipiproteinemie.

Info

Publication number
NL7900871A
NL7900871A NL7900871A NL7900871A NL7900871A NL 7900871 A NL7900871 A NL 7900871A NL 7900871 A NL7900871 A NL 7900871A NL 7900871 A NL7900871 A NL 7900871A NL 7900871 A NL7900871 A NL 7900871A
Authority
NL
Netherlands
Prior art keywords
hyperlipi
proteinemia
hyperlipidemia
procedure
therapeutic treatment
Prior art date
Application number
NL7900871A
Other languages
English (en)
Dutch (nl)
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT4790078A external-priority patent/IT1104165B/it
Priority claimed from IT4935378A external-priority patent/IT1156739B/it
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of NL7900871A publication Critical patent/NL7900871A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NL7900871A 1978-02-03 1979-02-02 Werkwijze voor de therapeutische behandeling van hyperlipidemie en hyperlipiproteinemie. NL7900871A (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT4790078A IT1104165B (it) 1978-02-03 1978-02-03 Nuova applicazione terapeutica della carnitina della acetil-carnitina e di altri derivati acilati della carnitina
IT4935378A IT1156739B (it) 1978-05-15 1978-05-15 Applicazione terapeutica della carnitina

Publications (1)

Publication Number Publication Date
NL7900871A true NL7900871A (nl) 1979-08-07

Family

ID=26329244

Family Applications (1)

Application Number Title Priority Date Filing Date
NL7900871A NL7900871A (nl) 1978-02-03 1979-02-02 Werkwijze voor de therapeutische behandeling van hyperlipidemie en hyperlipiproteinemie.

Country Status (6)

Country Link
US (1) US4255449A (fr)
JP (1) JPS54113409A (fr)
CH (1) CH640414A5 (fr)
DE (1) DE2903558C2 (fr)
GB (1) GB2013495A (fr)
NL (1) NL7900871A (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1156741B (it) * 1978-05-15 1987-02-04 Sigma Tau Ind Farmaceuti Applicazione terapeutica della carnitina e di alcuni derivati acilati della carnitina nell'emodialisi
DE2921852A1 (de) * 1979-05-29 1980-12-11 Fresenius Chem Pharm Ind Lipide senkendes mittel
IT1119853B (it) * 1979-09-21 1986-03-10 Sigma Tau Ind Farmaceuti Composizione farmaceutica comprendente l-carnitina per il trattamento delle dislipidemie ed iperlipo proteinemie
IT1142934B (it) * 1981-11-06 1986-10-15 Sigma Tau Ind Farmaceuti Uso della carnitina e delle acilcarnitine inferiori nel trattamento terapeutico della patologia delle vene
IT1157238B (it) * 1982-10-29 1987-02-11 Sigma Tau Ind Farmaceuti Impiego di 1-carnitina per migliorare i paramenti biochimici e comportamentali dell'eta' senile
CH655005A5 (it) * 1983-02-16 1986-03-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare.
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5550289A (en) * 1985-01-07 1996-08-27 Syntex (U.S.A.) Inc. N-(1,(1-1)-dialkyloxy)-and N-(1,(1-1)-dialkenyloxy alk-1-yl-N-N,N-tetrasubstituted ammonium lipids and uses therefor
JPH0667833B2 (ja) * 1985-11-28 1994-08-31 雪印乳業株式会社 経腸栄養剤
JP2518636B2 (ja) * 1987-02-13 1996-07-24 雪印乳業株式会社 重症感染症及び広範囲熱症治療経腸栄養剤
IT1231944B (it) * 1989-05-05 1992-01-16 Sigma Tau Ind Farmaceuti Composizione farmaceutica per il trattamento di protozoosi, particolarmente della tripasonomiasi comprendente d-carnitina o un alcanoilderivato della d-carnitina
CA2018137C (fr) * 1989-06-14 2000-01-11 Thomas Scholl Citrate magnesique de l-carnitine
US5073376A (en) * 1989-12-22 1991-12-17 Lonza Ltd. Preparations containing l-carnitine
JP2543382Y2 (ja) * 1991-10-22 1997-08-06 住友電装株式会社 フラットワイヤーハーネス
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6129930A (en) * 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US20060263428A1 (en) * 1993-09-20 2006-11-23 Eugenio Cefali Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6080428A (en) * 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
IT1276253B1 (it) 1995-12-15 1997-10-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o alcanoil l-carnitine per la prevenzione ed il trattamento di stati morbosi
IT1291127B1 (it) * 1997-04-01 1998-12-29 Sigma Tau Ind Farmaceuti Integratore alimentare per soggetti dediti ad intensa e prolungata attivita' fisica
IT1294227B1 (it) * 1997-08-01 1999-03-24 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l-carnitina e alcoli alifatici a lunga catena utile per la prevenzione
IT1306178B1 (it) * 1999-07-27 2001-05-30 Sigma Tau Ind Farmaceuti Uso della l-carnitina e dei suoi alcanoil derivati per la preparazionedi un medicamento utile nel trattamento del paziente affetto da
IT1307278B1 (it) * 1999-11-18 2001-10-30 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento di disturbi dovutiad un alterato metabolismo dei lipidi, che comprende propionil
DE10128934A1 (de) * 2001-06-18 2003-02-06 Bernhard Sibbe Wirkstoffzusammensetzung zur Vorbeugung gegen Angina-Pectoris-Beschwerden
US20030194423A1 (en) 2002-04-15 2003-10-16 Mars, Inc. Composition for enhancing nutritional content of food
DE10331202A1 (de) 2003-07-10 2005-03-31 S.K. Enterprise Gmbh Verwendung von Molkenpermeat zur Behandlung des Metabolischen Syndroms
US8173618B2 (en) * 2003-07-25 2012-05-08 University Of Massachusetts Formulations for reducing neuronal degeneration
US20070072910A1 (en) * 2005-09-29 2007-03-29 Smith Michael L Compositions and methods for lowering plasma concentrations of low density lipoproteins in humans
CN101505783B (zh) 2005-11-11 2013-09-04 V·R·钱德兰 作为抗血小板剂、营养补充剂和维生素补充剂的乙酰化氨基酸
DE102006036285A1 (de) 2006-08-03 2008-02-07 "S.U.K." Beteiligungs Gmbh Fraktionen aus Molkepermeat und deren Verwendung zur Prävention und Therapie des Typ-2 Diabetes und des Metabolischen Syndroms
US7777071B2 (en) * 2006-08-11 2010-08-17 Ssv Therapeutics, Inc. Production of carnitine conjugate intermediates
JP5214249B2 (ja) 2006-11-09 2013-06-19 三菱レイヨン株式会社 ベタインの製造方法
US20080279967A1 (en) * 2007-05-10 2008-11-13 Marvin Heuer Composition and method for increasing the metabolism of free fatty acids and facilitating a favorable blood lipid
US20080279968A1 (en) * 2007-05-10 2008-11-13 Marvin Heuer Composition and method for inducing lipolysis and increasing the metabolism of free fatty acids
US8597640B2 (en) * 2007-10-31 2013-12-03 University Of Massachusetts Lowell Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging
EP2353596A1 (fr) 2010-02-02 2011-08-10 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Composition combinée comprenant en tant que principes actifs de la L-carnitine ou de la propionyl L-carnitine pour la prévention d'une insuffisance veineuse chronique
AU2012251818B2 (en) 2011-05-03 2017-04-13 Alfasigma S.p.A Composition useful for the treatment of lipid metabolism disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1435916A (en) * 1972-05-11 1976-05-19 Beecham Group Ltd Pharmaceutical weight-reducing compositions
US3810994A (en) * 1972-06-01 1974-05-14 Ethyl Corp Method and composition for treating obesity
US3830931A (en) * 1972-11-06 1974-08-20 Felice S De Carnitine and its use in the treatment of arrhythmia and impaired cardiac function
US3968241A (en) * 1972-11-06 1976-07-06 Defelice Stephen L Method of treating cardiac arrhythmias and of improving myocardial contractility and systolic rhythm with carnitive or a pharmaceutically acceptable salt thereof
US4032641A (en) * 1976-06-09 1977-06-28 Tanabe Seiyaku Co., Ltd. Nicotinoyl carnitine derivatives

Also Published As

Publication number Publication date
GB2013495A (en) 1979-08-15
DE2903558C2 (de) 1994-09-01
CH640414A5 (it) 1984-01-13
US4255449A (en) 1981-03-10
DE2903558A1 (de) 1979-08-09
JPS54113409A (en) 1979-09-05
JPS649287B2 (fr) 1989-02-16

Similar Documents

Publication Publication Date Title
NL7900871A (nl) Werkwijze voor de therapeutische behandeling van hyperlipidemie en hyperlipiproteinemie.
AU507920B2 (en) The treatment of waste
NL7901961A (nl) Werkwijze voor het bereiden van een geneesmiddel voor de profylaxe en therapie van prostaathyperplasie.
NL188681C (nl) Geneesmiddel voor het verbeteren van de doorbloeding en wondgenezing.
NL188078C (nl) Farmaceutisch preparaat voor de behandeling van hartarrhytmieen en myocardiale aandoeningen.
NL7904912A (nl) Werkwijze voor de bereiding van tertiaire alkenen.
NL7504500A (nl) Werkwijze voor de gescheiden winning van vanadium en molybdeen.
NO154492C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme forbindelser.
NL7708951A (nl) Werkwijze voor de behandeling van vast radio- aktief afval.
HU178841B (en) Cattle-leader for the prophylactic or therapeutic treatment of cattle
NL7804026A (nl) Installatie en werkwijze voor de behandeling van metal- lurgische slakken.
NL7811823A (nl) Nieuwe oximen werkwijze voor de bereiding van oxyderen en oximen bevattend therapeutisch preparaat.
NO794063L (no) Fremgangsmaate til behandling av utskillingsherdbare ikke-jern-materialer.
NL7811106A (nl) Werkwijze voor de bereiding van moranoline en n-methylmoranoline.
NL7812394A (nl) Werkwijze voor de o-hydroxymethylering van aporfines.
NL7802848A (nl) Werkwijze voor de bereiding en toepassing van gesubstitueerde bisbenzimidazolylverbindingen.
NL7903251A (nl) Werkwijze voor de bereiding van cefalosporinen.
NL7904856A (nl) Staal en werkwijze voor de bereiding van staal.
NL188524C (nl) Werkwijze voor de bereiding van p-aminofenol.
NL7810337A (nl) Werkwijze voor de bereiding van alkyl- en alkylideen- thiosulfaten.
NL7812403A (nl) Farmaceutisch preparaat voor de behandeling van diarree bij de mens.
NO147103C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme forbindelser
NL7706439A (nl) Werkwijze voor de bereiding van bicyclo-dode- cylperoxydicarbonaat en toepassing daarvan.
NL7502574A (nl) Werkwijze voor de bereiding van 2-pyrrolidonen.
NL189650C (nl) Farmaceutische preparaten voor het behandelen van wonden.

Legal Events

Date Code Title Description
A85 Still pending on 85-01-01
BA A request for search or an international-type search has been filed
BB A search report has been drawn up
BC A request for examination has been filed
BV The patent application has lapsed